PMID- 11156721
OWN - NLM
STAT- MEDLINE
DCOM- 20010208
LR  - 20051116
IS  - 1042-3931 (Print)
IS  - 1042-3931 (Linking)
VI  - 12 Suppl E
DP  - 2000 Dec
TI  - Antithrombotic therapy in unstable angina/non-ST elevation myocardial infarction: 
      the evolving role of low-molecular-weight heparin.
PG  - E1-4;discussion E25-8
AB  - Acute coronary syndromes (ACS) represent a spectrum of diseases resulting from a 
      disturbance in myocardial blood flow. The etiology of this disturbance stems from 
      either partial or complete thrombotic occlusion of the culprit vessel. 
      Appropriate antithrombotic therapy is crucial in limiting the progression of ACS. 
      Conventional antithrombotic therapy in ACS has typically utilized unfractionated 
      heparin (UFH). However, UFH has several limitations that may restrict its 
      clinical usefulness. Direct antithrombin agents are currently not indicated for 
      ACS and have the potential for problems including a narrow therapeutic window and 
      bleeding. The low-molecular-weight heparins offer a convenient and attractive 
      alternative, which, in the case of enoxaparin, have demonstrated superiority over 
      UFH in two large randomized trials. Low-molecular-weight heparins (LMWH) 
      represent an important therapeutic advance in the management of ACS and 
      additional information is forthcoming that will better define the role of LMWH in 
      ACS.
FAU - Antman, E M
AU  - Antman EM
AD  - Cardiovascular Division, Brigham and Women s Hospital, 75 Francis Street, Boston, 
      MA, 02115, USA.
FAU - Kereiakes, D J
AU  - Kereiakes DJ
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - J Invasive Cardiol
JT  - The Journal of invasive cardiology
JID - 8917477
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
SB  - IM
MH  - Angina, Unstable/*drug therapy/physiopathology
MH  - Anticoagulants/*therapeutic use
MH  - *Electrocardiography
MH  - Heparin, Low-Molecular-Weight/*therapeutic use
MH  - Humans
MH  - Myocardial Infarction/*drug therapy/physiopathology
MH  - Thrombolytic Therapy/*methods
MH  - Treatment Outcome
RF  - 17
EDAT- 2001/01/13 11:00
MHDA- 2001/03/03 10:01
CRDT- 2001/01/13 11:00
PHST- 2001/01/13 11:00 [pubmed]
PHST- 2001/03/03 10:01 [medline]
PHST- 2001/01/13 11:00 [entrez]
PST - ppublish
SO  - J Invasive Cardiol. 2000 Dec;12 Suppl E:E1-4;discussion E25-8.